| DB ID | MyCo_1781 |
| Title | The prognostic virtue of inflammatory markers during late-onset sepsis in preterm infants |
| Year | 2004 |
| PMID | 15085896 |
| Fungal Diseases involved | Fungal sepsis |
| Associated Medical Condition | None |
| Genus | Candida |
| Species | spp. |
| Organism | Candida spp. |
| Ethical Statement | The research ethics committee at Neonatal Intensive Care Unit (NICU) approved the study and informed consent was obtained from the parents. |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | CRP |
| Biomarker Full Name | C-reactive protein |
| Biomarker Type | Prognostic |
| Biomolecule | Protein |
| Geographical Location | Israel |
| Cohort | This study was carried out at the Neonatal Intensive Care Unit (NICU) of Meir Hospital over a 26-month period ending in December 2001. All preterm infants who had a birth weight of less than 1750 g and who suffered from LOS were enrolled con- secutively into the study. Of 42 preterm infants that were evaluated: 10 had fulminant sepsis and 32 non-fulminant sepsis. |
| Cohort No. | 42 |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Late-onset sepsis (LOS) is an important cause of morbidity and mortality in preterm infants w5, 11, 18x. Despite advances in neonatal intensive care in recent decades, the incidence of sepsis-associated mortality has remained constant at nearly 15% w1x, in part due to a nonspecific initial manifestation of infection and a lack of defined prognostic markers. Defining specific clinical and inflammatory variables associated with the severity of the disease could potentially result in a more targeted adjunctive treatment. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | SAA Kit (Hemagen, Diagnostics, Waltham, MA,USA), Tina-quant (Boehringer-Mannheim, Mannheim, Germany), ELISA Kit from R&D Systems (MN, USA) |
| Assay Data | None |
| Validation Techniques used | ELISA |
| Up Regulation Down Regulation | Decrease |
| Sequence Data | None |
| External Link | None |
